New Data Alert on the Up-and-Coming Migraine Medication: Intranasal Zavegepant. While not yet approved for release, intranasal Zavegepant has shown promise in some interesting and unique data points in the relief of acute migraine. What is Zavegepant and what will it offer us that is different from the other medications made newly available?

Listen to Lindsay Weitzel, PhD, ask the tough questions of migraine clinical trial expert Tim Smith, MD, about this up-and-coming medication.

***UPDATE 3/10/2023 - Zavegepant is the first FDA-Approved CGRP nasal spray for acute migraine. Zavegepant will be available to patients in July 2023.